tetano
Editor, Senior Moderator
J Antimicrob Chemother
. 2021 Nov 25;dkab432.
doi: 10.1093/jac/dkab432. Online ahead of print.
Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city
Julia Jeck[SUP] 1 [/SUP], Florian Jakobs[SUP] 1 2 3 [/SUP], Anna Kron[SUP] 1 2 3 4 [/SUP], Oliver A Cornely[SUP] 2 4 5 6 7 [/SUP], Florian Kron[SUP] 1 2 4 8 [/SUP]
Affiliations
Abstract
Objectives: Internationally, healthcare systems are confronted by an ever-increasing scarcity of medical resources due to the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to investigate the impact of remdesivir on the demand of hospital bed capacities for hospitalized COVID-19 patients and to evaluate the potentially created capacities for treating additional COVID-19 patients or elective treatments at the hospital.
Methods: An epidemiological model was developed that utilized the population of Cologne (Germany) during the first COVID-19 wave (first hospitalized patient-30 September 2020) to compare two scenarios: no administration of remdesivir (A) and the administration of remdesivir according to the EMA label (B). The results of the Adaptive COVID-19 Treatment Trial were used to evaluate the potential impact of remdesivir on hospital capacity.
Results: With the first recorded patient on 2 March 2020, a total of 576 COVID-19 hospitalized patients were detected during the first wave in Cologne. Comparing both scenarios (A versus B) of the model, the administration of remdesivir increased the number of discharges from 259 to 293 (+5.8%) and fewer patients needed ICU admission [214 versus 178 (-6.3%)]. In addition, the model estimated 20 fewer deaths (scenario B). Based on a reduced length of stay, 31.4 hospital beds (57.0 versus 25.6) could have been freed by administering remdesivir to eligible patients. This would have allowed either the treatment of an additional 730 COVID-19 patients or 660 elective treatments.
Conclusions: In our model, remdesivir administration profoundly contributed to free hospital capacities in the metropolitan city Cologne in Germany.
. 2021 Nov 25;dkab432.
doi: 10.1093/jac/dkab432. Online ahead of print.
Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city
Julia Jeck[SUP] 1 [/SUP], Florian Jakobs[SUP] 1 2 3 [/SUP], Anna Kron[SUP] 1 2 3 4 [/SUP], Oliver A Cornely[SUP] 2 4 5 6 7 [/SUP], Florian Kron[SUP] 1 2 4 8 [/SUP]
Affiliations
- PMID: 34849943
- DOI: 10.1093/jac/dkab432
Abstract
Objectives: Internationally, healthcare systems are confronted by an ever-increasing scarcity of medical resources due to the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to investigate the impact of remdesivir on the demand of hospital bed capacities for hospitalized COVID-19 patients and to evaluate the potentially created capacities for treating additional COVID-19 patients or elective treatments at the hospital.
Methods: An epidemiological model was developed that utilized the population of Cologne (Germany) during the first COVID-19 wave (first hospitalized patient-30 September 2020) to compare two scenarios: no administration of remdesivir (A) and the administration of remdesivir according to the EMA label (B). The results of the Adaptive COVID-19 Treatment Trial were used to evaluate the potential impact of remdesivir on hospital capacity.
Results: With the first recorded patient on 2 March 2020, a total of 576 COVID-19 hospitalized patients were detected during the first wave in Cologne. Comparing both scenarios (A versus B) of the model, the administration of remdesivir increased the number of discharges from 259 to 293 (+5.8%) and fewer patients needed ICU admission [214 versus 178 (-6.3%)]. In addition, the model estimated 20 fewer deaths (scenario B). Based on a reduced length of stay, 31.4 hospital beds (57.0 versus 25.6) could have been freed by administering remdesivir to eligible patients. This would have allowed either the treatment of an additional 730 COVID-19 patients or 660 elective treatments.
Conclusions: In our model, remdesivir administration profoundly contributed to free hospital capacities in the metropolitan city Cologne in Germany.